Forum » General » News and Announcements » Novartis sees strong interest in Sandoz generics unit

Novartis sees strong interest in Sandoz generics unit

  • 1 23888
    You have lifted a basic offspring..Blesss for using..I would need to think about better most recent exchanges from this blog..preserve posting.. 먹튀폴리스
      February 8, 2022 3:27 AM MST
    0
  • 1 23888
    Mmm.. admirable to be here in your report or tell, whatever, I notoriety I ought to besides process solid for my have site need I play some salubrious further refreshed occupied in your area. 안전놀이터
      January 22, 2022 5:33 AM MST
    0
  • 1 23888
    Welcome to the gathering of my life here you will master every little thing about me. 바카라사이트
      January 20, 2022 4:38 AM MST
    0
  • The reason why safety is the most important among game sites is because it is unstable when used in unsafe spaces  안전카지노사이트
      January 17, 2022 8:48 PM MST
    0
  • 1 23888
    I welcome you to the page where you can read with intriguing data on comparable points. 온라인카지노
      January 16, 2022 3:06 AM MST
    0
  • 1 23888
    Benefit as much as possible from primarily premium substances - you will discover him or her for: 안전놀이터
      January 13, 2022 7:46 AM MST
    0
  • 1 23888
    For genuine devotees of this string I will address is a free on the web! 바카라사이트
      January 13, 2022 7:06 AM MST
    0
  • 10258
    This substance is just energizing and innovative. I have been settling on an institutional move and this has helped me with one angle.  먹튀검증커뮤니티
      January 3, 2022 6:47 AM MST
    0
  • 1 23888
    I went onto your blog while centering just marginally submits. Decent procedure for next, I will be bookmarking without a moment's delay grab your entire ascents... FinQuiz
      January 2, 2022 10:43 PM MST
    0
  • 1 23888
    안전놀이터 추천 전문 뱃조이 입니다. 사설토토 메이저놀이터 업체를 확실하게 검증 후 안전하게 이용 가능한 최고의 토토사이트 목록을 안내합니다.먹튀 없이 이용 가능한 스포츠토토 및 온라인 카지노사이트 리스트를 저희 뱃조이 에서 확인 바랍니다. 사설토토 추천
      December 27, 2021 4:29 AM MST
    0
  • 1 23888
    There is such a great amount in this article I could never have thought of alone. Your substance gives perusers things to consider in a fascinating way. 메이저놀이터
      December 20, 2021 1:31 AM MST
    0
  • 1 23888
    This is extremely fascinating substance! I have altogether delighted in perusing your focuses and have arrived at the conclusion that you are ideal about a significant number of them. You are incredible. เล่นเกมได้เงิน
      December 15, 2021 3:34 AM MST
    0
  • 1 23888
    In this specific article, you will see a synopsis, fulfill peruse this post. 먹튀검증사이트
      December 14, 2021 4:10 AM MST
    0
  • Novartis is seeing strong interest from private equity investors as well as from other pharmaceuticals companies for the Sandoz generic drugs business it is considering selling, Chief Executive Vas Narasimhan said in a newspaper interview.To get more latest news on novartis, you can visit shine news official website.

    “We have seen considerable interest from private equity firms as well as other companies in the market,” Narasimhan told Swiss newspaper Finanz und Wirtschaft.

    “We have to do our work internally first to be able to provide financial data to some of the interested parties. That takes time. Within a year, we want to have clarity,” the CEO added.

    The Swiss pharmaceuticals company raised the prospect of divesting Sandoz in October.

    All options remain open, including keeping Sandoz as part of Novartis, spinning it off to shareholders, or selling it to another company, the executive said in the interview published on Saturday.He declined to give a possible price tag for Sandoz, which achieved sales of $9.7 billion last year, about 20% of the group total.

    “If we currently read that there are offers for 10 or 20 billion, we should not take this too seriously,” he said.

    “Such offers are primarily put forward by analysts and then by the media, not by us or by real interested parties. We have to wait for the actual negotiations.”

    Novartis was looking to use some of the $21 billion proceeds from selling its 33% stake in Roche for acquisitions, Narasimhan said, although patience was required because of high market valuations.

    The company was interested in acquisitions in areas such as cardiovascular diseases, immunology, neurology, hematology or oncology, he said.

    But Narasimhan declined to comment on rumours linking Novartis with U.S. biotech company Alnylam or Swiss drugmaker Vifor Pharma.
      December 13, 2021 7:10 PM MST
    0